SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
Investigators have discovered the mechanisms underlying a T-cell receptor's immunosuppressive function, according to a study published Nature Immunology, findings that may provide insight into the ...
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the ...
This is an illustration of how the engineered protein facilitates destruction of latently HIV-infected immune cells. 1) Protein and cells, from left to right: engineered protein with yellow-and-black ...
The FDA granted accelerated approval to talquetamab-tgvs for treatment of certain patients with relapsed or refractory multiple myeloma. The indication authorizes use of the agent for adults who ...
Less than a week after approving Johnson & Johnson’s bispecific antibody, Talvey (talquetamab-tgvs), for relapsed or refractory multiple myeloma (r/r MM) under accelerated review, the U.S. FDA has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback